{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:27:48Z","timestamp":1787063268246,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06099-8","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T17:33:16Z","timestamp":1732555996000},"page":"5285-5296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of TSRP reverses imatinib resistance through the PI3K \/ Akt pathway in chronic myeloid leukemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Ying","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"6099_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2012.0184","volume":"10","author":"J Cortes","year":"2012","unstructured":"Cortes J, Goldman JM, Hughes T (2012) Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw 10:S1\u2013S13. https:\/\/doi.org\/10.6004\/jnccn.2012.0184","journal-title":"J Natl Compr Canc Netw"},{"key":"6099_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bcmd.2014.02.008","volume":"53","author":"AF Ferreira","year":"2014","unstructured":"Ferreira AF, Moura LG, Tojal I (2014) ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Blood Cells Mol Dis 53:47\u201355. https:\/\/doi.org\/10.1016\/j.bcmd.2014.02.008","journal-title":"Blood Cells Mol Dis"},{"key":"6099_CR3","doi-asserted-by":"publisher","unstructured":"Almeida TP, Ferreira J, Vettorazzi A, Azqueta A, Rocha E, Ramos AA\u00a0(2018) Cytotoxic activity of fucoxanthin, alone and in combination with the cancer drugs imatinib and doxorubicin, in CML cell lines. Environ Toxicol Pharmacol 59:24\u201333.\u00a0https:\/\/doi.org\/10.1016\/j.etap.2018.02.006","DOI":"10.1016\/j.etap.2018.02.006"},{"key":"6099_CR4","doi-asserted-by":"publisher","unstructured":"Kantarjian H, O'Brien S, Jabbour E et al (2011) Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 29:3173\u20133178.\u00a0https:\/\/doi.org\/10.1200\/JCO.2010.33.4169","DOI":"10.1200\/JCO.2010.33.4169"},{"key":"6099_CR5","doi-asserted-by":"publisher","unstructured":"Jabbour E, Jones D, Kantarjian HM et al (2009) Long-term outcome of patients chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114:2037\u20132043. https:\/\/doi.org\/10.1182\/blood-2009-01-197715","DOI":"10.1182\/blood-2009-01-197715"},{"key":"6099_CR6","doi-asserted-by":"publisher","unstructured":"Gruber FX, Ernst T, Porkka K, Engh\u00a0RA et al (2012) Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia 26(1):172\u2013177. https:\/\/doi.org\/10.1038\/leu.2011.187","DOI":"10.1038\/leu.2011.187"},{"key":"6099_CR7","first-page":"385","volume":"43","author":"Q Dai","year":"2018","unstructured":"Dai Q, Ge Y (2018) Inhibition of proliferation and mechanism of platycodon platycodon D combined with imatinib on K562 \/R cells with leukemia resistance. Chin J Tradit Chin Med 43:385\u2013389","journal-title":"Chin J Tradit Chin Med"},{"key":"6099_CR8","doi-asserted-by":"publisher","unstructured":"Gao J, Sun CR, Yang JH et al (2011) Evaluation of the hepatoprotective and antioxidant activities of Rubus parvifolius L. J Zhejiang Univ Sci B 12(2):135\u2013142. https:\/\/doi.org\/10.1631\/jzus.B1000117","DOI":"10.1631\/jzus.B1000117"},{"key":"6099_CR9","unstructured":"Zheng Z, Zhang L, Huang C et al (2007) Study on the antitumor effect of total saponins of Cymbidium japonicum on melanoma. Chin J Tradit Chin Med 32(19):2055\u20132058. https:\/\/doi.org\/10.3321\/j.issn:1001-5302.2007.19.024"},{"key":"6099_CR10","doi-asserted-by":"publisher","unstructured":"Xu X, Zhang X, Feng J (2011) Experimental study on the inhibitory effect of Maomaoberry and its drug-containing serum on K562 leukemia cells. Chin Med Sci Technol 18(5):408\u2013410. https:\/\/doi.org\/10.3969\/j.issn.1005-7072.2011.05.028","DOI":"10.3969\/j.issn.1005-7072.2011.05.028"},{"key":"6099_CR11","first-page":"1790","volume":"8","author":"Xu Xiaofeng","year":"2011","unstructured":"Xu X, Zhang X, Feng J (2011) Experimental study on the effects of berry and its total saponins on K562 leukemia cells. J Chin Med 29(8):1790\u20131794","journal-title":"J Chin Med"},{"key":"6099_CR12","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.13193\/j.issn.1673-7717.2015.07.037","volume":"33","author":"Xu Xiaofeng","year":"2015","unstructured":"Xu X, Chen R, Yang B et al (2015) Study on the mechanism of apoptosis induced by total saponins, homoharringtonine and cytarabine in leukemia cells in vitro. J Chin Med 33(7):1659\u20131663. https:\/\/doi.org\/10.13193\/j.issn.1673-7717.2015.07.037","journal-title":"J Chin Med"},{"key":"6099_CR13","doi-asserted-by":"publisher","unstructured":"Xu X, Yang W, Zhang X (2017) Study on the synergistic induction of apoptosis of leukemia HL-60 cells by total saponins combined with chemotherapeutics through Fas pathway. J Chin Med 35(4):923\u2013926. https:\/\/doi.org\/10.13193\/j.issn.1673-7717.2017.04.041","DOI":"10.13193\/j.issn.1673-7717.2017.04.041"},{"key":"6099_CR14","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.7314\/APJCP.2014.15.13.5455","volume":"15","author":"YQ Ge","year":"2014","unstructured":"Ge YQ, Xu XF, Yang B et al (2014) Saponins from Rubus parvifolius L. induce apoptosis in human chronic myeloid leukemia cells through AMPK activation and STAT3 inhibition. Asian Pac J Cancer Prev 15(13):5455\u20135461. https:\/\/doi.org\/10.7314\/apjcp.2014.15.13.5455","journal-title":"Asian Pac J Cancer Prev"},{"key":"6099_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11655-013-1537-0","volume":"20","author":"ZHANG Xue-jin","year":"2014","unstructured":"Zhang\u00a0XJ, Xu XF, Gao\u00a0RL\u00a0et al (2014) Rubus Parvifolius L.Inhibited the Growth of Leukemia K562 Cells in Vitro and in Vivo. Chin J Integr Med 20(1):36\u201342. https:\/\/doi.org\/10.1007\/s11655-013-1537-0","journal-title":"Chin J Integr Med"},{"key":"6099_CR16","doi-asserted-by":"publisher","unstructured":"Xu XF, Cheng RB, Zhang XJ (2018) Total saponins of Rubus Parvifolius L. exhibited anti-leukemia effect in vivo through STAT3 and elF4E signaling pathways. Chin J Inter Med 24(2):920\u2013924. https:\/\/doi.org\/10.1007\/s11655-018-2563-8","DOI":"10.1007\/s11655-018-2563-8"},{"key":"6099_CR17","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2016.68.6931","volume":"34","author":"L Fornaro","year":"2016","unstructured":"Fornaro L, Vasile E, Falcone A (2016) Apatinib in advanced gastric cancer: a doubtful step forward. J Clin Oncol 34(31):3822\u20133833. https:\/\/doi.org\/10.1200\/JCO.2016.68.6931","journal-title":"J Clin Oncol"},{"issue":"Suppl_10","key":"6099_CR18","doi-asserted-by":"publisher","first-page":"x12","DOI":"10.1093\/annonc\/mdz381","volume":"30","author":"B Verret","year":"2019","unstructured":"Verret B, Crotes J, Bachelot T et al (2019) Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol 30(Suppl_10):x12\u2013x20. https:\/\/doi.org\/10.1093\/annonc\/mdz381","journal-title":"Ann Oncol"},{"issue":"1","key":"6099_CR19","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1038\/s41467-021-23752-2","volume":"12","author":"V Ecker","year":"2021","unstructured":"Ecker V, Stumpf M, Brandmeier L et al (2021) Targeted PI3K\/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. Nat Commun 12(1):3526. https:\/\/doi.org\/10.1038\/s41467-021-23752-2","journal-title":"Nat Commun"},{"issue":"12","key":"6099_CR20","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1158\/2159-8290.CD-20-0815","volume":"11","author":"J Xu","year":"2021","unstructured":"Xu J, Yu X, Martin TC et al (2021) AKT Degradation Selectively Inhibits the Growth of PI3K\/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. Cancer Discov 11(12):3064\u20133089. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0815","journal-title":"Cancer Discov"},{"key":"6099_CR21","first-page":"463","volume":"18","author":"J Wang","year":"2017","unstructured":"Wang J, Yin Z (2017) Research progress on chemical constituents and pharmacology of Rubus parvifolius L. China Pharm 18:463\u2013464","journal-title":"China Pharm"},{"key":"6099_CR22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031\u20131037. https:\/\/doi.org\/10.1056\/NEJM200104053441401","journal-title":"N Engl J Med"},{"key":"6099_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H (2016) Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 91(2):252\u2013265. https:\/\/doi.org\/10.1002\/ajh.24275","journal-title":"Am J Hematol"},{"key":"6099_CR24","doi-asserted-by":"publisher","first-page":"e3961","DOI":"10.17795\/ijcp-3961","volume":"9","author":"S Tabarestani","year":"2016","unstructured":"Tabarestani S, Movafagh A (2016) New developments in chronic myeloid leukemia: implications for therapy. Iran J Cancer Prev 9(1):e3961. https:\/\/doi.org\/10.17795\/ijcp-3961","journal-title":"Iran J Cancer Prev"},{"key":"6099_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","volume":"22","author":"PA Pophali","year":"2016","unstructured":"Pophali PA, Patnaik MM (2016) The role of new tyrosine kinase inhitors in chronic myeloid leukemia. Cancer J 22(1):40\u201350. https:\/\/doi.org\/10.1097\/PPO.0000000000000165","journal-title":"Cancer J"},{"key":"6099_CR26","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"Jorge Cortes","year":"2015","unstructured":"Cortes J, Pavlovsky C, Sau\u00dfele S (2021) Chronic myeloid leukaemia. Lancet 398(10314):1914\u20131926. https:\/\/doi.org\/10.1016\/S0140-6736(21)01204-6","journal-title":"Lancet"},{"key":"6099_CR27","doi-asserted-by":"publisher","first-page":"5828","DOI":"10.1158\/1078-0432.CCR-13-0258","volume":"19","author":"O Frankfurt","year":"2013","unstructured":"Frankfurt O, Licht JD (2013) Ponatinib-a step forward in overcoming resistance in chronic myeloid leukemia. Clin Cancer Res 19(21):5828\u20135834. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0258","journal-title":"Clin Cancer Res"},{"key":"6099_CR28","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367(22):2075\u20132088. https:\/\/doi.org\/10.1056\/NEJMoa1205127","journal-title":"N Engl J Med"},{"key":"6099_CR29","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.2174\/1568026620666201019111524","volume":"20","author":"L-Y Zhang","year":"2020","unstructured":"Zhang L-Y, Zhang J-G, Yang X (2020) Targeting tumor immuno-suppressive microenvironment for the prevention of hepatic cancer: applications of traditional Chinese medicines in targeted delivery. Curr Top Med Chem 20(30):2789\u20132800. https:\/\/doi.org\/10.2174\/1568026620666201019111524","journal-title":"Curr Top Med Chem"},{"key":"6099_CR30","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","volume":"19","author":"A Burchert","year":"2005","unstructured":"Burchert A, Wang Y, Cai D, von Bubnoff N (2005) Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development. Leukemia 19(10):1774\u20131782. https:\/\/doi.org\/10.1038\/sj.leu.2403898","journal-title":"Leukemia"},{"key":"6099_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.leukres.2017.05.015","volume":"59","author":"E Yap","year":"2017","unstructured":"Yap E, Norziha ZA, Simbun A(2017) MicroRNAs that affect the Fanconi Anemia\/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations. Leuk Res 59:32\u201340. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.015","journal-title":"Leuk Res."},{"key":"6099_CR32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/leu.2009.49","volume":"23","author":"R Naughton","year":"2009","unstructured":"Naughton R, Quiney C, Turner SD (2009) Bcr-Abl-mediated redox regulation of the PI3K\/AKT pathway. Leukemia 23(8):432\u20131440. https:\/\/doi.org\/10.1038\/leu.2009.49","journal-title":"Leukemia"},{"key":"6099_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4161\/cbt.26725","volume":"15","author":"S Okabe","year":"2014","unstructured":"Okabe S, Tauchi T, Tanaka Y (2014) Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biol Ther 15(2):207\u2013215. https:\/\/doi.org\/10.4161\/cbt.26725","journal-title":"Cancer Biol Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06099-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06099-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06099-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:14:32Z","timestamp":1735848872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06099-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6099"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06099-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4907396\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies \/ procedures have been approved by China Ethics Committee and performed in accordance with the ethical standards. The Animal experiment protocol listed below has been reviewed and approved by Laboratory animal of Zhejiang Eyong Pharmaceutical Research & Development Co., Ltd (protocol code: ZJEY-20230420\u201306 and the date of approval: April 20, 2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statements"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}